21 results about "Bone erosion" patented technology

The invention relates to the technical field of image data processing, in particular to a rheumatism immune disease joint injury assessment system based on image recognition. The system comprises a joint image preprocessing module, an image segmentation and injury characteristic analysis module, a bone erosion and synovial thickening evaluation module and a joint injury evaluation and injury visualization module, can obtain joint image data of the rheumatism immune disease, perform size scaling and image denoising processing, and perform joint part image segmentation at the same time. Image data of the joint part region of the rheumatism immune disease is obtained; and performing joint injury structural feature analysis and joint image injury quantitative evaluation on the joint partial region image data of the rheumatism immune disease to obtain a joint image injury score corresponding to the rheumatism immune disease patient, and performing evaluation to obtain a joint image injury type to perform joint injury visualization so as to obtain a joint injury visual image result. The joint injury degree corresponding to the joint image of the rheumatism immune disease can be more accurately detected.

The invention discloses a rheumatoid arthritis targeted therapeutic drug and a preparation method thereof, and relates to the field of medicines. The invention relates to an acid response nano-particle CEC NPs, which is specifically composed of the following components: a carrier, which is an M2 type macrophage derived exosome; and loading the medicine. According to the acid response nano-particles based on the CXB and the CC-90011 loaded on the exosome derived from the M2 type macrophage, the M2Exo can specifically target an inflammatory environment, and the specific anti-inflammatory biological function of the M2Exo can be exerted; under the acidic condition, CEC NPs responds to release CE NPs and CC-90011, the CE NPs can repolarize M1 type macrophages and inhibit FLS activation to effectively relieve arthritis inflammatory response and synovial hyperplasia, and the CC-90011 can inhibit LSD1 to interfere the energy metabolism pathway of osteoclasts and inhibit osteoclast formation, so that the pathological bone resorption process is blocked, and bone erosion is relieved.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The application discloses application of myrtenal in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The application verifies for the first time that myrtenal can block the RA inflammatory cascade from multiple aspects, and overcomes the limitation that single-target treatment is easy to produce drug resistance. Specifically, myrtenal can reduce the levels of inflammatory factors and metal proteins; inhibit the proliferation, migration and invasion of synovial fibroblasts SFs; inhibit the expression of glycolysis-related genes, reduce sugar metabolites; inhibit the synovial tissue hyperplasia, inflammatory cell infiltration, bone erosion and bone destruction of mice joints; promote the mental state of arthritis mice to be obviously improved, the food intake to be increased, the hair to be shiny, the joint swelling to be subsided, the bruise of the ankle joint to be subsided, the skin to be improved, and the activity to be sensitive. Therefore, the application proposes a new medical use of myrtenal in treating rheumatoid arthritis, and develops a brand-new therapeutic indication of myrtenal.

The invention discloses a supramolecular compound and a preparation method and application thereof.The supramolecular compound is carrier-free nanoparticles (CDN) obtained by conducting molecular self-assembly on tripterine (CeL) and demethylwedelolactone, and experiments show that the CDN can effectively relieve clinical symptoms, inflammation infiltration and bone erosion. Besides, the CDN can be transferred to an inflammation part of rheumatoid arthritis (RA) in a targeted manner, so that bone degenerative change and joint skeleton damage can be remarkably reduced, the inflammation part is targeted, the expression of proinflammatory cytokines is reduced, the drug concentration of the affected part is improved, and the toxic and side effects of the tripterine are reduced. The research provides a new strategy for improving the curative effect and safety of the traditional Chinese medicine, and provides a brand new solution for RA treatment.

The invention relates to the technical field of Tibetan medicine preparations, in particular to a Tibetan medicine composition for treating rheumatoid arthritis and a preparation method. The Tibetan medicine composition is prepared from 18 Tibetan medicines including fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit and the like according to a specific weight ratio, and the monarch, minister, assistant and guide relationship is defined based on the Tibetan medicine true brucellosis theory; according to the preparation method, a low-temperature superfine grinding and step-by-step extraction process is innovatively adopted, three dosage forms of powder, a nano drug-loaded emulsion and a temperature-sensitive acupoint patch are developed, and a dual quality control system of HPLC (High Performance Liquid Chromatography) content determination and fingerprint spectrum is established. TNF-alpha and IL-6 target spots and nf-kb and PI3K-AKT inflammation pathways are synergistically regulated and controlled through multiple components, joint swelling and bone erosion are relieved, and gastrointestinal tract side effects of western medicines are avoided; the transdermal absorption efficiency is improved by a nano drug-loading technology, acupoint targeted drug delivery is realized by the temperature-sensitive patch, and verification shows that the joint swelling inhibition rate is greater than or equal to 70%, the inflammatory factor decrease amplitude is greater than or equal to 50%, and the patch is suitable for patients with mild, moderate and severe rheumatoid arthritis and has a wide clinical application prospect.

The invention discloses an application of rotigotine microspheres in preparation of medicines for preventing or treating rheumatic arthritis, the rotigotine microspheres can directly act on joint parts, joint synovial hyperplasia, joint injury and bone erosion are effectively reduced, and the curative effect of the rotigotine microspheres is improved. The rotigotine microspheres can be independently used or matched with other known medicines, compounds or carriers to be prepared into various forms of medicaments or pharmaceutical compositions for prevention or treatment, and the dopamine receptor can be continuously excited for 4-8 weeks by injecting once during administration, so that the'on-off 'phenomenon caused by fluctuation of blood concentration is remarkably improved, and the bioavailability of the rotigotine microspheres is improved. Therefore, the curative effect can be effectively improved, and the compliance of a patient is greatly improved.

The present invention belongs to the technical field of drug preparation, and discloses a drug for treating knee osteoarthritis, a preparation method and an application thereof. It is composed of 20 g of Rehmanniae Radix, 15 g of Epimedii Folium, 15 g of Drynariae Rhizoma, 12 g of Angelicae Sinensis Radix, 12 g of Polygoni Cuspidati Rhizoma et Radix, and 10 g of Achyranthis Bidentatae Radix by weight. In the present invention, Rehmanniae Radix for tonifying the kidney and generating essence is used as the monarch drug, Epimedii Folium and Drynariae Rhizoma for tonifying the liver and kidney and strengthening the bones and muscles are used as the ministerial drugs, Angelicae Sinensis Radix and Polygoni Cuspidati Rhizoma et Radix for promoting blood circulation to remove stasis and relieve pain are used as the adjuvant drugs, and Achyranthis Bidentatae Radix for conducting the drugs downward to reach the affected site is used as the messenger drug. The combination of various drugs exerts the effects of tonifying the liver and kidney, strengthening the bones and muscles, and activating blood circulation and dredging collaterals. The various drugs work together, each performing its own function and synergistically exerting the curative effect. On the basis of long-term clinical practice, the present invention puts forward the pathogenesis concept of kidney deficiency and bone erosion, prolonged illness invading collaterals, and finally resulting in the coexistence of kidney deficiency and stasis. Through clinical research and animal experiment verification, the drug formula has significant curative effect and high safety in the treatment of knee osteoarthritis.

The present invention relates to a computer-implemented method for clustering defects of defective bones and manufacturing a patient-specific orthopaedic implant, including at least the following steps: - acquiring computed tomography CT images of a defective or damaged bone and feeding a database; - given a set of defective bones retrieved from said defective or damaged bone database, reconstructing a synthetic shape of the original shape of the defective bone; - computing a bone erosion depth map of said synthetic shape of the original shape of the defective bone, where said bone erosion depth map, for a given defective bone, comprises a set of erosion values over the region of interest of the reconstructed bone, defining an erosion vector; - transforming said erosion depth map into an erosion matrix which comprises the erosion vectors of the defective bones and the vertices over the surface of the region of interest of said synthetic shape of the original shape of the defective bone; - feeding said erosion matrix to an unsupervised machine learning algorithm that groups data into a tree of nested clusters, to identify clusters of relevant bone defects and to generate synthetic three-dimensional bone models representative of each defect cluster; - associating a defect label to each cluster; - training a defect classifier using said erosion matrix and said defect label to classify clusters of defects of the bones; - feeding a CAD environment with the outputs of said defect classifier; - creating the orthopaedic implant based on the outputs fed to the CAD environment.

The invention relates to the technical field of biological medicine, and provides application of ginkgolide A as a novel traditional Chinese medicine monomer in treatment of rheumatoid arthritis. The invention discloses application of ginkgolide A, a crystal form of ginkgolide A, pharmaceutically acceptable salt of ginkgolide A or a combination of ginkgolide A and crystal form of ginkgolide A to preparation of a medicine for treating rheumatoid arthritis as an active ingredient. Researches in the embodiment of the invention prove that bilobalide A can significantly inhibit mouse joint swelling and joint inflammation, and has a good anti-inflammatory effect; the MicroCT scanning shows that compared with the model group, the bone damage of the treatment group is obviously reduced. In addition, the ginkgolide A is used for preparing the medicine for treating rheumatoid arthritis, and has remarkable advantages in clinical application and social and economic benefits.

The invention discloses a use method of a nuciferine-containing rheumatoid arthritis bone erosion resistant composition, and relates to the field of rheumatoid arthritis bone erosion treatment.The use method comprises the steps that 1, an applicable object is determined, and the applicable object is a patient suffering from rheumatoid arthritis and having the bone erosion condition; according to the invention, the applicable object is determined to be a patient with rheumatoid arthritis and bone erosion, so that the treatment is more targeted, unnecessary use of medicines in non-target people is avoided, the utilization efficiency of medical resources is improved, and potential risks possibly brought by the medicines to non-applicable people are reduced; the nuciferine not only has remarkable anti-inflammatory activity in vitro, but also remarkably relieves the process of CIA rat arthritis in vivo, and the nuciferine relieves inflammatory response by reducing expression levels of inflammatory factors TNF-alpha, IL-1beta and IL-6 and total IgG, IgG1 and IgG2a of immune globulins in CIA rat serum.

The invention relates to application of abacavir in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. The abacavir is found to be capable of relieving related symptoms of rheumatoid arthritis for the first time, and particularly, abacavir is proved to be capable of inhibiting joint swelling and bone erosion of mice and relieving pathological phenotypes in a collagen-induced arthritis mouse model; meanwhile, in a peripheral blood mononuclear cell (PBMCs) sample of a patient with rheumatoid arthritis, abacavir is found to be capable of reducing expression of interferon stimulated gene (ISGs) family related genes, so that abacavir can be used as a novel therapeutic drug for rheumatoid arthritis. In conclusion, abacavir can be used as a medicine for treating rheumatoid arthritis and has very high clinical application value.

The invention provides an ultrasonic image processing method, ultrasonic equipment and a storage medium. The ultrasonic image processing method comprises the following steps: inputting an ultrasonic image of a target object into a trained target detection model to obtain a first region of interest in the ultrasonic image and a first number corresponding to the first region of interest; and determining the bone erosion degree of the target object based on the first region of interest and the first number. And under the condition that the bone erosion degree meets a preset condition, at least displaying the ultrasonic image. The target detection model in the method is obtained based on the ultrasonic training image, the second region of interest corresponding to the ultrasonic training image, and the second number corresponding to the ultrasonic training image. According to the scheme, through an automatic means, the influence of clinical experience of a user on the accuracy of the determined bone erosion degree is avoided, and the labor cost can also be reduced, especially under the condition that the ultrasonic image is an image in the ultrasonic video.

The invention discloses dual-drug-loading temperature-sensitive composite hydrogel as well as a preparation method and application thereof. The composite hydrogel comprises a temperature-sensitive hydrogel matrix, an anti-inflammatory natural medicine extract and composite microspheres, wherein the anti-inflammatory natural medicine extract and the composite microspheres are dispersed in the temperature-sensitive hydrogel matrix; the composite microspheres comprise hydrogel microspheres loaded with bone-strengthening traditional Chinese medicine extracellular vesicles. The composite hydrogel disclosed by the invention has a'microsphere-gel 'composite system, local long-acting slow release and efficient anti-inflammation of an anti-inflammatory natural medicine extract are realized by utilizing a temperature-sensitive hydrogel matrix, and more importantly, bone-strengthening traditional Chinese medicine plant-derived extracellular vesicles are packaged in hydrogel microspheres as active ingredients; the nano-material can act on a bone joint interface in a targeting manner, and can promote osteogenesis and inhibit osteoclast enduringly, so that two major core pathological processes of RA inflammation and bone erosion are intervened at the same time.

This invention provides a deep learning-based method and system for identifying bone erosion in X-ray images of rheumatoid arthritis, belonging to the field of image analysis technology. The invention acquires the frequency domain texture chaos degree and geometric grayscale manifold data of the image; inputs these data into a differentiable entropy-weighted topological neural network, and uses the frequency domain texture entropy as dynamic weights to reconstruct a simplex filtering sequence, generating a continuous homogeneous landscape feature tensor representing the pathological structure; cross-domain stitching and upsampling are then performed through a multi-scale feature fusion decoding network to generate a lesion probability mask; simultaneously, environmental adaptive degradation control is triggered in real time based on statistical dispersion. This effectively solves the problems of high-frequency texture detail loss and noise sensitivity in existing technologies, achieving accurate localization and robust identification of small bone erosion lesions under low-dose X-ray images.

The application relates to application of abacavir in preparation of a drug for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. It is found for the first time that abacavir can relieve the related symptoms of rheumatoid arthritis, and specifically, it is proved in a collagen-induced arthritis mouse model that abacavir can inhibit joint swelling and bone erosion of the mouse, and relieve the pathological phenotype; meanwhile, it is found in peripheral blood mononuclear cell (PBMCs) samples of rheumatoid arthritis patients that the use of abacavir can reduce the expression of interferon stimulated gene (ISG) family related genes, which indicates that the abacavir can be used as a new type of drug for treating rheumatoid arthritis. In summary, the abacavir can be used as a drug for treating rheumatoid arthritis, and has high clinical application value.

The application relates to application of FGFR as an inhibition target in preparation of a drug for treating rheumatoid arthritis, and the application of the inhibitors Pemigatinib, Erdafitinib, Infigratinib and Sufatinib can obviously reduce the area of bone erosion by a vascular pannus cell, and the application proves that the inhibitors can be used for preparing a drug for treating rheumatoid arthritis, provides a new treatment for treating rheumatoid arthritis, and has a good application prospect.

The invention discloses an application of 50% alcohol elution part (50% SOE) of herba siegesbeckiae in preparation of a medicine for treating osteoclast of rheumatoid arthritis. Researches show that 50% SOE has better anti-inflammatory and osteoclast differentiation inhibition effects than alcohol elution parts with other concentrations. LC-MS / MS analysis shows that 50% SOE mainly contains terpenoid and flavonoid components, and 50% SOE with different concentrations has relatively good biological safety. By constructing a collagen-induced arthritis (CIA) mouse model, it is shown that 50% SOE can significantly inhibit the arthritis process of the CIA mouse, inhibit the foot swelling degree of the CIA mouse and improve the conditions of soft tissue swelling, osteoporosis, joint deformity and bone erosion of the CIA mouse, has a good effect of treating RA and can be used for preparing more drugs for treating and resisting rheumatoid arthritis bone destruction.

The invention relates to application of tazeostat or pharmaceutically acceptable salt thereof in preparation of medicines for preventing and / or treating rheumatoid arthritis and / or diseases caused by rheumatoid arthritis. It is found for the first time and proved through experiments that the tazeostat or the pharmaceutically acceptable salt thereof can obviously reduce joint swelling, joint morphological change, bone erosion and other symptoms of rheumatoid arthritis and shows a remarkable treatment effect on rheumatoid arthritis, and the treatment effect of the tazeostat or the pharmaceutically acceptable salt thereof is obviously superior to that of drugs in the prior art. In addition, the inventor also finds that the tazeostat and the methotrexate have an obvious synergistic interaction effect in the aspect of treating the rheumatoid arthritis. In view of the above, the tazeostat is expected to become a candidate therapeutic drug for rheumatoid arthritis or related diseases thereof, and has great clinical application prospects and values.

Methods and apparatuses (e.g., devices and systems) for nerve stimulation to treat bone erosion, including in patients for having an inflammatory and / or autoimmune conditions, such as, but not limited to, rheumatoid arthritis (RA). In some cases, these methods may reduce or prevent bone erosion by applying electrical stimulation of the nerve (e.g., vagus nerve) in a patient that is desensitized to electrical nerve simulation to suppress inflammation (e.g., by decreasing cytokines such as RANK-L). In some cases this may include applying electrical energy in a manner that would desensitize the suppression of anti-inflammatory cytokines while reducing or preventing bone erosion. Alternatively or additionally, these methods may include applying electrical energy to a subject that is already desensitized to the electrical modulation of cytokines (e.g., RANKL) by nerve stimulation.

The invention provides a sacroiliac joint X-ray image intelligent grading method comprising the following steps: carrying out CT value remapping on a DR image through an adaptive filtering core to obtain an artifact-removed image; segmenting the sacrum and the ilium through a neural network model to obtain sacroiliac joints; performing affine transformation on the artifact-removed image to obtain a standardized image; performing three-dimensional reconstruction on the standardized image to obtain a reconstructed image, and extracting an articular cavity depth coefficient; performing multi-scale feature fusion on the reconstructed image to obtain multi-scale features; based on the reconstructed image, performing time domain evolution through a space-time double-flow network to obtain a bone erosion area change rate; and performing logistic regression fusion on the articular cavity depth coefficient, the bone erosion area change rate and the multi-scale features to obtain a grading result. According to the method, through adaptive artifact filtering, multi-scale spatial-temporal feature fusion and pathological region weight optimization, the problems of structural offset and dynamic feature deficiency caused by noise interference are solved, and the recognition precision and efficiency are improved.